Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
International Association of Sickle Cell Nurses and Professional AssociatesThe International Association of Sickle ...
-
Shengdar Q. Tsai, PhDDr. Shengdar Q. Tsai is an assistant mem...
-
Higher Prevalence of Hydroxyurea Use Is Associated with Lower Hospitalization Rate in a Population of Children with ...Background: Individuals with sickle cel...
-
Sickle Cell Disease: Data Saves Lives“One minute I’d be fine, the next mi...
-
Allistair Abraham, MDAllistair Abraham is currently affiliate...
-
The Sickle Cell Infusion Center at Johns HopkinsThe Sickle Cell Center for Adults is ded...
-
A survey of sickle cell patients transitioned to adult care from Texas children’s hematology center between Januar...An estimated 93-98% of sickle cell disea...
